glp 1 and medicare coverage Recent Trends in GLP-1 Use Spending in Medicare GLP-1 Bridge Program –

doi: 10.1042/BSR20171284 213 RobinsonALubitzIAtrakchi-BaranesDLicht-MuravaAKatselPLeroithDet al

The optimal approach requires individualised assessment considering disease activity, nutritional status, comorbidities, and patient preferences, delivered through multidisciplinary collaboration between gastroenterology, dietetics, and weight management services

Underlying medical conditions can make weight loss feel impossible

(2020) 105:e2192206

In a 10-week clinical trial, a daily dose of 20 mg oral semaglutide achieved a steady-state plasma concentration of 30 nM, and when daily dose of oral semaglutide was increased to 40 mg, the semaglutide plasma concentration reached about 60 nM (102), which was over a thousand times higher than the EC50 of semaglutide for GLP-1R activation (95)